SpeeDx Pty Ltd

1400 Barbara Jordan Blvd
Austin,  TX  78723

United States
https://plexpcr.com/

• Booth: 105

SpeeDx develop innovative multiplex real-time polymerase chain reaction (qPCR) solutions, and specialize in detection of infectious disease pathogens and antimicrobial resistance markers. The SpeeDx product portfolio spans sexually transmitted infections (STIs), respiratory conditions and more. With streamlined product development and manufacturing, SpeeDx is equipped to rapidly respond to your needs.

 Press Releases

• Exciting expansion as SpeeDx adds concise gastroenteritis panels to their R (Apr 29, 2024)

  EntericPlex^* products Sharpen Your Focus

  SpeeDx have released a suite of gastroenteritis panels, the three EntericPlex RUO assays, each with up to 5 targets in a single-well multiplexed qPCR/NAAT assay⎯differing from much more extensive and expensive low-throughput panels. Research relevant pathogens ⎯ maximize efficiency with focused enteric panels. Choose from our range of concise enteric panels detecting common parasitic or bacterial gastroenteric pathogens.

  EntericPlex Parasite^*, EntericPlex Bacteria I^*, and EntericPlex Bacteria II^* detect a range of common bacterial and parasite targets, allowing researchers to focus on relevant targets.

  Learn more:
  US based – click here
  Not US based – click here

  Read Full Press Release here

  *SpeeDx EntericPlex Assays are Research Use Only, and not to be used in Diagnostic Procedures

• SpeeDx launch next generation PCR multiplexing technology (Apr 29, 2024)

  Inaugural RespiV PlexPlus^®* product showcases advantages

  SpeeDx unveils a new innovative spin on qPCR technology that doubles the standard target output. Without requiring specialized equipment, the new PlexPlus^® technology does all the work whilst utilizing existing standard qPCR instrumentation in laboratories.

  Launched today RespiV PlexPlus^®, the first product to harness this next generation multiplexing technology, simultaneously detects 14 respiratory viral targets in a single well, namely influenza A virus, influenza B virus, severe acute respiratory syndrome coronavirus 2, respiratory syncytial viruses A and B, adenoviruses B and C, human parainfluenza viruses 1, 2, 3 and 4, human metapneumovirus, rhinovirus and human enterovirus. This is the first of many products powered by PlexPlus^® technology coming through the SpeeDx pipeline.

  Read Press Release

   

  ^*RespiVPlexPlus^® product is Research Use Only, not for use in diagnostic procedures.

• SpeeDx announce expansion of their research offering. (Apr 29, 2024)

  SpeeDx Pty. Ltd., have released a new Research Use Only (RUO) product providing an exciting expansion of their research offering. CT/GC/TV/MGPlex* simultaneously detects Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) in a single-well multiplex qPCR/NAAT assay.

  CT/GC/TV/MGPlex is the missing piece, paving the way for a streamlined STI research workflow providing maximal results, utilising open extraction and qPCR/NAAT platforms. From a single sample extraction, you can combine detection of these four key STI organisms, with the ability to determine antibiotic resistance with SpeeDx’s flagship Antimicrobial Resistance (AMR) products, PlexPrime^® MG+23S and PlexPrime^® GC+gryA.

  Read press release

  Learn More

 Additional Info